Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
2010
Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment
2013 Standout
Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2016
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
2008
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
2011
RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells
2010
Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
2010
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer
2016
Breast cancer
2019 Standout
Updated UK Recommendations for HER2 assessment in breast cancer
2014
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
2011
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
2012
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
2011 Standout
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
2018
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
2018
Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data
2020
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Neoadjuvant Therapy in the Treatment of Breast Cancer
2014
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
2015
Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer Therapy
2012
Fertility Management for Women With Cancer
2007
Targeted therapies in breast cancer: are heart and vessels also being targeted?
2012
Breast cancer
2016 Standout
Targeted Therapy for Breast Cancer
2013
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international Breast Cancer Study Group (IBCSG) trial VI
1998
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
2019
Do Adults Change Their Lifestyle Behaviors After a Cancer Diagnosis?
2003
The biology and management of non-small cell lung cancer
2018 StandoutNature
Primary Care for Survivors of Breast Cancer
2000
Change in Women’s Diet and Body Mass Following Intensive Intervention for Early-stage Breast Cancer
2001
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
2010
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
The Cancer Genome Atlas Pan-Cancer analysis project
2013 Standout
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
2017
Osteopenia and osteoporosis in women with breast cancer
2003
Ovarian function and childbearing issues in breast cancer survivors
2007
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Global cancer statistics
2011 Standout
Primary ovarian insufficiency
2010
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
2004 Standout
A Good Drug Made Better: The Fulvestrant Dose-Response Story
2014
Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010
2011
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2013
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study
2002
Predictors of ovarian reserve in young women with breast cancer
2007
Ovarian function preservation in the cancer patient
2004
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Fertility Preservation Methods in Breast Cancer
2012
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Gastric cancer
2020 Standout
Breast Cancer in Limited-Resource Countries: Health Care Systems and Public Policy
2006
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
2014
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
The PI3K Pathway in Human Disease
2017 Standout
Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence
2004
Guideline implementation for breast healthcare in low-income and middle-income countries
2008
International Adaptations of NCCN Clinical Practice Guidelines in Oncology
2014
Fertility preservation in female patients
2004
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Side Effects of Adjuvant Treatment of Breast Cancer
2001
Preservation of Fertility in Patients with Cancer
2009 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Trends in mortality from major cancers in the Americas: 1980–2010
2014
Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study
2018
Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer
2005
Leading the Way in Exercise and Diet (Project LEAD):
2003
Riding the Crest of the Teachable Moment: Promoting Long-Term Health After the Diagnosis of Cancer
2005 Standout
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Nutrition and Survival After the Diagnosis of Breast Cancer: A Review of the Evidence
2002
Secondary Amenorrhea After Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin’s Lymphoma Study Group
2005
Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer
2008
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
2013
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
2014 StandoutNobel
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations
2015
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Breast Cancer Treatment
2019 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Childbearing issues in breast carcinoma survivors
1997
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Fertility Preservation in Breast Cancer Patients: A Prospective Controlled Comparison of Ovarian Stimulation With Tamoxifen and Letrozole for Embryo Cryopreservation
2005
Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3‐98
2013
The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource‐Stratified Phased Implementation: Methods and overview
2020
Early-Stage Imaging of Nanocarrier-Enhanced Chemotherapy Response in Living Subjects by Scalable Photoacoustic Microscopy
2014
Quality of Life in Goserelin-Treated Versus Cyclophosphamide + Methotrexate + Fluorouracil–Treated Premenopausal and Perimenopausal Patients With Node-Positive, Early Breast Cancer: The Zoladex Early Breast Cancer Research Association Trialists Group
2003
Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcinomas
2000
Association between current lifestyle behaviors and health-related quality of life in breast, colorectal, and prostate cancer survivors
2004
Global cancer statistics, 2012
2015 Standout
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
2013
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Risk of Menopause During the First Year After Breast Cancer Diagnosis
1999
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Standout
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
2012
Primary Systemic Therapy of Breast Cancer
2006
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
2009
Works of José Bines being referenced
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
2008
Outcomes of Breast Cancer in Brazil Related to Health Care Coverage: A Retrospective Cohort Study
2013
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer
2010
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer
2006
Breast Cancer in Limited-Resource Countries: Treatment and Allocation of Resources
2006
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
2012
Guideline implementation for breast healthcare in low- and middle-Income countries: Treatment resource allocation
2008
Evidence-Based Neoadjuvant Endocrine Therapy for Breast Cancer
2006
Effective but cost-prohibitive drugs in breast cancer treatment
2008
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial
2014
Long-term toxic effects of adjuvant chemotherapy in breast cancer
2011
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.
1996
96137544 Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer
1996
Primary care issues for the breast cancer survivor.
1997
Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT
2008
NEWEST: a Phase II, randomised, neoadjuvant trial comparing fulvestrant 500 mg vs 250 mg in postmenopausal women with locally advanced, oestrogen receptor-positive (ER+) breast cancer
2008
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
2017